The Food and Drug Administration (FDA) has granted Fast Track designation for VX15 (Vaccinex) as a potential treatment for Huntington’s disease (HD).
The Company has initiated a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate VX15 in patients with late prodromal (pre-manifest) and early manifest HD in June 2015. A complete interim analysis of the trial is anticipated in the third quarter of 2016 and detailed data to be available in 2018.
VX15 is a novel, investigational monoclonal antibody designed to block the activity of semaphorin 4D (SEMA4D), a molecule believed to promote chronic inflammatory responses in the brain.
For more information visit Vaccinex.com.